Bigger budgets, fewer accounts. That’s the dilemma facing pharma marketers as drugmakers consolidate work.
Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?
March 13, 2018
9:14 pm
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
Pharma companies, now marketing high-science drugs, rely more on medical affairs
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they’re called upon early and often.
